{"id":755522,"date":"2025-08-06T16:36:01","date_gmt":"2025-08-06T16:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=755522"},"modified":"2025-08-06T16:36:01","modified_gmt":"2025-08-06T16:36:01","slug":"complicated-skin-and-soft-tissue-infections-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-micurx-pharmaceuticals-inc-basilea-pharmaceutica","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/complicated-skin-and-soft-tissue-infections-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-micurx-pharmaceuticals-inc-basilea-pharmaceutica_755522.html","title":{"rendered":"Complicated skin and soft tissue infections Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | MicuRx Pharmaceuticals Inc., Basilea pharmaceutica"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/08\/1754460076.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Complicated skin and soft tissue infections Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | MicuRx Pharmaceuticals Inc., Basilea pharmaceutica\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/08\/1754460076.jpg\" alt=\"Complicated skin and soft tissue infections Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | MicuRx Pharmaceuticals Inc., Basilea pharmaceutica\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Complicated skin and soft tissue infections Pipeline Analysis<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cComplicated Skin and Soft Tissue Infections (cSSTI) &#8211; Pipeline Insight, 2025,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated Skin and Soft Tissue Infections (cSSTI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.<\/div>\n<p style=\"text-align: justify;\">Complicated skin and soft tissue infections Pipeline constitutes 5+ key companies continuously working towards developing 5+ Complicated skin and soft tissue infections treatment therapies, analyzes DelveInsight.<\/p>\n<p style=\"text-align: justify;\"><strong>Complicated skin and soft tissue infections Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Skin and soft tissue infections (SSTIs) represent a wide spectrum of frequently occurring infectious conditions that often demand prompt medical attention and hospitalization. The more serious variant, known as complicated SSTIs (cSSTIs), involves deeper layers of soft tissue and includes infections such as cellulitis, major abscesses, infected surgical wounds, burns, skin ulcers, and diabetic foot ulcers. Staphylococcus aureus is the most common pathogen responsible for cSSTIs. Management usually includes surgical procedures alongside antibiotic treatment, with antibiotic selection tailored to the patient&rsquo;s specific clinical condition.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a detailed insights report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Complicated skin and soft tissue infections pipeline insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Complicated skin and soft tissue infections Pipeline Insight 2025&#8221; report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Complicated skin and soft tissue infections Therapeutics Market.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Complicated skin and soft tissue infections Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&rsquo;s report on the Complicated Skin and Soft Tissue Infections (cSSTIs) pipeline highlights a dynamic and evolving landscape, with over five active companies working on more than five therapeutic candidates aimed at improving treatment options.<\/p>\n<\/li>\n<li>\n<p>Leading companies such as MicuRx Pharmaceuticals Inc., Basilea Pharmaceutica, and others are actively investigating novel drugs to enhance the management of cSSTIs. Among the promising candidates in development are Contezolid (MRX-I), Ceftobiprole medocaril, and several others at various clinical stages.<\/p>\n<\/li>\n<li>\n<p>Omadacycline, approved by the FDA in October 2018, is utilized for treating acute bacterial skin and skin structure infections as well as community-acquired bacterial pneumonia. It serves as a useful alternative for patients with cSSTIs, particularly in cases involving antibiotic resistance.<\/p>\n<\/li>\n<li>\n<p>Similarly, delafloxacin received FDA approval in June 2017 for treating acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Its broad-spectrum antibacterial activity makes it an important option in the treatment of cSSTIs.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Complicated skin and soft tissue infections Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights into the key companies that are developing therapies in the Complicated skin and soft tissue infections Market.<\/p>\n<\/li>\n<li>\n<p>The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complicated skin and soft tissue infections treatment.<\/p>\n<\/li>\n<li>\n<p>It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Complicated skin and soft tissue infections market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download our free sample page report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Complicated skin and soft tissue infections pipeline insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Complicated skin and soft tissue infections Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Contezolid (MRX-I): MicuRx Pharmaceuticals Inc.<\/p>\n<\/li>\n<li>\n<p>Ceftobiprole medocaril: Basilea Pharmaceutica<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Complicated skin and soft tissue infections Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Multiple leading companies are actively working on developing treatments for Complicated Skin and Soft Tissue Infections (cSSTIs). Notably, Basilea Pharmaceutica and others have drug candidates currently in mid-to-late stages of development, including Phase III clinical trials.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 5+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Complicated skin and soft tissue infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Complicated skin and soft tissue infections Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages to Get an in-depth Assessment of the Emerging Complicated skin and soft tissue infections Therapies and Key Companies: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Complicated skin and soft tissue infections Clinical Trials and advancements<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Complicated skin and soft tissue infections Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Complicated skin and soft tissue infections Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\">&bull; Complicated skin and soft tissue infections By Stage<\/p>\n<p style=\"text-align: justify;\">&bull; Complicated skin and soft tissue infections Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">&bull; Complicated skin and soft tissue infections Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\"><strong>Download Complicated skin and soft tissue infections Sample report to know in detail about the Complicated skin and soft tissue infections treatment market @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Complicated skin and soft tissue infections Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Complicated skin and soft tissue infections Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Complicated skin and soft tissue infections &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Complicated skin and soft tissue infections Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Complicated skin and soft tissue infections Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Complicated skin and soft tissue infections Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Complicated skin and soft tissue infections Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Complicated skin and soft tissue infections Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Complicated skin and soft tissue infections Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Complicated skin and soft tissue infections Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Complicated skin and soft tissue infections Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Complicated skin and soft tissue infections Analyst Review<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get Detailed Insights About the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Complicated skin and soft tissue infections Pipeline Reports Offerings<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=complicated-skin-and-soft-tissue-infections-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-micurx-pharmaceuticals-inc-basilea-pharmaceutica\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=complicated-skin-and-soft-tissue-infections-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-micurx-pharmaceuticals-inc-basilea-pharmaceutica\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Complicated skin and soft tissue infections Pipeline Analysis DelveInsight\u2019s, \u201cComplicated Skin and Soft Tissue Infections (cSSTI) &#8211; Pipeline Insight, 2025,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated Skin and Soft Tissue Infections (cSSTI) pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/complicated-skin-and-soft-tissue-infections-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-micurx-pharmaceuticals-inc-basilea-pharmaceutica_755522.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-755522","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/755522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=755522"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/755522\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=755522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=755522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=755522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}